Efficacy of Ustekinumab in Refractory Palmoplantar Pustular Psoriasis

C. Morales-Múnera; E. Vilarrasa, L. Puig


The British Journal of Dermatology. 2013;168(4):820-824. 

In This Article


All of our patients had severe manifestations of PPPP, with concomitant flares of psoriasis vulgaris in three patients. In addition, they had presented incomplete or no response to other treatments, including topical agents, photochemotherapy, ciclosporin, acitretin or methotrexate, and anti-TNF-α agents.

Positive responses to ustekinumab were initially seen in all of the patients, 2–3 weeks after the first dose, and were more remarkable after the second injection. Complete resolution of PPPP was achieved at week 20 and was maintained in all patients. We have not observed any flares or side-effects during the course of treatment (median duration of follow-up 15·2 months, range 11–23 months).